NEWS & UPDATES Phil Ball 10/15/24 Phil Ball 10/15/24 Tolerance Bio, Inc. Launches with $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases Read More
Phil Ball 10/15/24 Phil Ball 10/15/24 Tolerance Bio, Inc. Launches with $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases Read More
